Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | PKLR | P30613 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345810 | 0.90 | GPR119 (0.46) | TACR1GPR119TSHRALOX15ATM | |
| SCHEMBL15807270 | 0.81 | PKLR (0.47) | TACR1GPR119TSHRALOX15ATM | |
| SCHEMBL23868006 | 0.79 | MGLL (0.58) | TACR1GPR119MGLLLIPE | |
| SCHEMBL29470023 | 0.79 | MGLL (0.58) | TACR1GPR119MGLLLIPE | |
| SCHEMBL2344758 | 0.76 | EPHX2 (0.41) | EPHX2 | |
| SCHEMBL2340268 | 0.75 | EPHX2 (0.45) | EPHX2HDAC1HDAC2 | |
| SCHEMBL30700851 | 0.75 | LIPE (0.43) | GPR119MGLLLIPEOPRD1OPRK1 | |
| SCHEMBL14893759 | 0.75 | NR1I2 (0.48) | TACR1GPR119TSHRALOX15ATM | |
| SCHEMBL11963131 | 0.74 | STS (0.49) | TACR1TSHRALOX15ATMOPRD1 | |
| SCHEMBL8162238 | 0.74 | TACR1 (0.46) | TACR1GPR119OPRD1OPRK1PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358704-A1 | 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | Pfizer Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | TACR1 1624/4885GPR119 58/4885TSHR 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.